Kedudukan dalam Saham
#8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Harga Saham
$4.74
Disegerakkan terakhir: 2026-08-28
Perubahan (1 hari)
-5.77%
Perubahan (1 tahun)
-16.96%
Perdagangan Inventiva S.A. (IVA)
Harga IVA dengan permodalan pasaran b
Modal pasaran bagi Inventiva S.A.(IVA)
Modal Pasaran: $1.12B
Sehingga August 2026, Inventiva S.A. mempunyai modal pasaran sebanyak $1.12B. Ini menjadikan Inventiva S.A. syarikat ke-8990th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Inventiva S.A. dari 2017 hingga 2026
IVA berbanding dengan 5 teratas yang paling popular stocks
| Harga IVA |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.264T
|
+469,562.19%
|
|
|
|
|
$4.701T
|
+419,365.62%
|
|
|
|
|
$4.177T
|
+372,603.60%
|
|
|
|
|
$3.817T
|
+340,502.96%
|
|
|
|
|
$2.866T
|
+255,645.41%
|
